Ipriflavone suppresses NLRP3 inflammasome activation in host response to biomaterials and promotes early bone healing. (22nd June 2022)

• Record Type: Journal Article
• Authors: Chen, Yun; Li, Jia; Shi, Jue; Ning, Dandan; Feng, Jianying; Lin, Weiwei; He, Fuming; Xie, Zhijian
• Is Part Of: Journal of clinical periodontology. Volume 49:Number 8(2022)
• Page Start: 814
• Page End: 827
• Publication Date: 2022-06-22
• Subjects: implant -- ipriflavone -- macrophage -- NLRP3 inflammasome -- osseointegration; Periodontics -- Periodicals; 617.6
• DOI: 10.1111/jcpe.13647
• Languages: English
• ISSNs: 0303-6979

Abstract

Abstract: Aim: Emerging studies have shown that immune response to biomaterial implants plays a central role in bone healing. Ipriflavone is clinically used for osteoporosis. However, the mechanism of ipriflavone in immune response to implants in early stages of osseointegration remains unclear. In this study, we aimed to investigate the potential role of ipriflavone in early bone healing process and uncover the underlying mechanism. Materials and Methods: We carried out histological examination as well as analysis of proinflammatory cytokines and NLRP3 inflammasome activation in a tibial implantation mouse model with intra‐peritoneal injection of ipriflavone. In addition, we explored the mechanism of ipriflavone in the regulation of NLRP3 inflammasome activation in macrophages. Results: In vivo, ipriflavone ameliorated host inflammatory response related to NLRP3 inflammasome activation at implantation sites, characterized by reductions of inflammatory cell infiltration and proinflammatory cytokine interleukin‐1β levels. Ipriflavone treatment also showed beneficial effects on early osseointegration. Further investigations of the molecular mechanism showed that the suppression of NLRP3 inflammasome acts upstream of NLRP3 oligomerization through abrogating the production of reactive oxygen species. Conclusions: These results revealed an anti‐inflammatory role of ipriflavone in NLRP3 inflammasome activation through improving mitochondrial function. This study provides a new strategy for the development of immune‐regulated biomaterials and treatment options for NLRP3‐related diseases.